Total raised
$8.0M
Last: Series A 2012-09
Stage
Acquired
Founded
2010
Headcount
1-10
HQ
Hod HaSharon
Sector
Health Tech & Life Sciences
About
cCAM Biotherapeutics is a preclinical-stage company focused on the discovery and development of novel immunotherapies to treat cancer. The company's lead product, CM-24, is a phase 1 monoclonal antibody that inhibits the immunosuppressive effect of CEAC AM1, leading to an enhanced anti-tumor immune response of T and NK cells. cCAM Biotherapeutics' activity has been fully integrated into Merck & Co. Inc.
Funding history · 1 round · $8.0M total
2012-09
Series A
$8.0M
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is cCAM Biotherapeutics' primary focus?
- cCAM Biotherapeutics is a preclinical-stage company focused on the discovery and development of novel immunotherapies to treat cancer.
- What is the lead product of cCAM Biotherapeutics?
- cCAM Biotherapeutics' lead product is CM-24, a phase 1 monoclonal antibody designed to inhibit the immunosuppressive effect of CEACAM1, thereby enhancing anti-tumor immune responses of T and NK cells.
- When was cCAM Biotherapeutics founded?
- cCAM Biotherapeutics was founded in January 2010.
- When did cCAM Biotherapeutics initiate the Phase 1 trial for CM-24?
- In April 2015, cCAM Biotherapeutics announced the initiation of a Phase 1 trial for CM-24, its novel immune checkpoint inhibitor for cancer immunotherapy.
- What was the total amount raised by cCAM Biotherapeutics?
- cCAM Biotherapeutics raised a total of $8,000,000 USD. For a full financing history, please refer to startupim.
- Which investors participated in cCAM Biotherapeutics' Series A round?
- cCAM Biotherapeutics secured $8,000,000 in its Series A round in September 2012, with investors including Arkin Tech, OrbiMed, and Pontifax.
- When was cCAM Biotherapeutics acquired and by whom?
- cCAM Biotherapeutics was acquired by Merck in July 2015, leading to its status as an inactive company.
- What was the acquisition amount for cCAM Biotherapeutics?
- In July 2015, Merck acquired cCAM Biotherapeutics for an amount of $95,000,000 USD.
- What is the current operational status of cCAM Biotherapeutics?
- cCAM Biotherapeutics is currently inactive, as its activities have been fully integrated into Merck & Co. Inc. following its acquisition in July 2015.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Tags
therapeuticscancerpharmaceuticalsimmunologytreatmentspharma-companies